Ad
related to: nanobody drug approved
Search results
Results From The WOW.Com Content Network
Envafolimab is an anti-PD-L1 nanobody used in cancer immunotherapy. [1] It has been approved in China for the treatment of microsatellite instability-high (MSI-H) or MisMatch Repair deficient (dMMR) solid tumours. [2] Envafolimab (KN035) has obtained the US FDA's orphan drug designation for advanced biliary tract cancer.
Ozoralizumab (trade name Nanozora) is a trivalent anti-tumour necrosis factor alpha (TNFα) nanobody designed for the treatment of inflammatory diseases. [1] Ozoralizumab was developed by Pfizer Inc, and now belongs to Ablynx NV. Ablynx has licensed the rights to the antibody in China to Eddingpharm.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
GoodRx released a list of 19 of the most influential drugs and vaccines approved by the FDA in 2024 to treat a variety of conditions. These medications are “slated to make a big clinical impact."
A single-domain antibody is a peptide chain of about 110 amino acids long, comprising one variable domain (V H) of a heavy-chain antibody, or of a common IgG.These peptides have similar affinity to antigens as whole antibodies, but are more heat-resistant and stable towards detergents and high concentrations of urea.
Like Eisai and Biogen's rival drug Leqembi, which was approved a year ago, donanemab is designed to clear an Alzheimer's-related protein called beta amyloid from the brain.
Bi-specific T-cell engager (BiTE) is a class of artificial bispecific monoclonal antibodies that are investigated for use as anti-cancer drugs. They direct a host's immune system, more specifically the T cells ' cytotoxic activity, against cancer cells.
Lilly applied to the FDA for approval of the drug in July, after late-stage clinical trial data showed it slowed the progression of Alzheimer’s by 29% after 18 months, compared to a placebo.